Figure 2
From: Polycomb-mediated silencing in neuroendocrine prostate cancer
Coordinated increase in PcG gene expression. (A) Average fold change of non-PcG and PcG genes from unselected 147 EpR list and selected 22 EpR list. (B) Expression of typical prostate neuroendocrine (SYP, CHGA) and adenocarcinoma (AR, PSA) markers in selected xenograft models. (C) Coordinated upregulation of core PRC1 and PRC2 members led by CBX2 and EZH2 in selected xenograft models. (D) Significant correlation between PcG gene expression in all LTL xenograft models and 331R/331 model.